Karen Seiter is an Oncology physician affiliated with New York Medical College. OpenAlex indexes 213 publications with 4,497 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
19 Bradhurst Ave
Suite 2100
Hawthorne, NY 105322140
Telephone
914-493-8375Provider last certified this registry record 10 Oct 2025.
Clinical trials
- Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Sponsor: New York Medical College
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202520 payments$26,504openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20255 payments$10,451openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.9%Kinase inhibitor21.6%Jakafi30%Brukinsa21%Imbruvica16%Sprycel10%Iclusig9%Imatinib Mesylate7%Sorafenib7%Part D<11 patientsThalidomide Analog13.7%Revlimid76%Lenalidomide12%Pomalyst12%Part D<11 patients+ 5 more classes in this area
Dermatology
14.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.3%Acyclovir100%Part D≥42 patientsAnti-infectives
9.5%Azole Antifungal5.7%Fluconazole100%Part D≥21 patientsFluoroquinolone Antibacterial2.2%Levofloxacin100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Mitchell Cairo, MD
New York Medical College
Leslie Citrome, MD, MPH
New York Medical College
Jerry Nadler
New York Medical College
Allen Dozor, MD
New York Medical College
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”